GlassScriptPhysician profile
Rama Nadella
NPI 1659545457
$8,085.68
in general payments reported to CMS, 2019-2025
29 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $1,117 · 2021: $528 · 2022: $1,263 · 2023: $1,473 · 2024: $1,567 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,296 · Education: $2.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,296.36 |
| Education | $2.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,791.79 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $789.81 | 2020-2025 | Benlysta |
| Horizon Therapeutics Plc | $773.93 | 2019-2023 | Krystexxa |
| Amgen INC. | $737.67 | 2019-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $631.96 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $455.52 | 2019-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $432.68 | 2023-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $347.43 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Opko Pharmaceuticals, LLC | $299.48 | 2019-2024 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $238.80 | 2019-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $222.47 | 2021-2024 | Lupkynis |
| Novo Nordisk INC | $213.21 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $205.35 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $180.71 | 2024-2025 | |
| Baxter Healthcare | $117.79 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.09 | 2023-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $96.22 | 2020-2025 | Acthar |
| Akebia Therapeutics INC | $90.52 | 2021-2025 | Vafseo |
| Nxstage Medical, INC. | $72.69 | 2022 | |
| Renalytix Ai, INC. | $62.67 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ani Pharmaceuticals, INC. | $48.03 | 2022 | |
| Cormedix INC. | $45.23 | 2024-2025 | Defencath, Defencath |
| Travere Therapeutics, INC. | $25.64 | 2022-2023 | |
| Ardelyx, INC. | $23.05 | 2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $22.65 | 2020 | |
| Recor Medical INC | $19.22 | 2024 | Paradise Renal Denervation System |
| Ethicon US, LLC | $17.71 | 2019 | |
| Apellis Pharmaceuticals, INC. | $15.36 | 2025 | Empaveli |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rama Nadella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.